A Phase 3 clinical trial investigating hypofractionated, dose-escalation radiotherapy for high-risk prostate cancer reached its primary completion on 2026-01-31. The study enrolled 329 participants to evaluate this treatment approach.
Background
Prostate cancer is a significant health concern, with hundreds of thousands of men diagnosed annually in North America, and tens of thousands succumbing to the disease each year. The increasing incidence, partly due to an aging population and prostate specific antigen (PSA) screening, places substantial demand on cancer care services. For patients with high-risk prostate cancer, external beam radiation therapy (EBRT) combined with two to three years of hormonal manipulation (luteinizing hormone-releasing hormone [LHRH] agonists) is a common treatment strategy.
Trial design
This Phase 3 study, titled 'Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate,' enrolled 329 participants. The trial focused on patients with Prostate Cancer and aimed to investigate a hypofractionated, dose-escalation radiotherapy approach.
What this means
The primary completion of this Phase 3 trial marks a significant milestone in the evaluation of hypofractionated, dose-escalation radiotherapy for high-risk prostate cancer. While specific results are not yet available, the completion of this phase indicates that the primary data collection period has concluded. Future analysis of the collected data will be crucial for understanding the efficacy and safety profile of this treatment strategy and its potential implications for patient care.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT01444820, detailing the 'Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate' trial, was updated with this event on 2026-01-31 on clinicaltrials.gov.